title: Physicians' acceptable treatment failure rates in antibiotic therapy for coagulase-negative staphylococcal catheter-associated bacteremia: implications for reducing treatment duration.
abstract: BACKGROUND
  Decreasing the duration of antimicrobial therapy is an attractive strategy for delaying the emergence of antimicrobial resistance. Limited data regarding optimal treatment durations for most clinical infections hinder the adoption of this approach and impair optimal physician-patient communication under the shared decision-making model. We aimed to identify acceptable failure rates among infectious disease consultants (IDCs) for treatment of central venous catheter-associated bacteremia.
  
  
  METHODS
  A case scenario involving a representative patient who developed central venous catheter-associated bacteremia caused by coagulase-negative staphylococci and who received standard-of-care therapy was distributed to all nonpediatric IDC members of the Infectious Diseases Society of America's Emerging Infections Network in August 2003. Each member was suggested 1 of 10 treatment failure rates and asked whether he or she would accept or reject the given value. Logistic regression was used to evaluate the relationship between specific failure rates offered to respondents and their willingness to accept them using a methodology derived from contingent valuation.
  
  
  RESULTS
  Among the 374 respondents (response rate, 54%), the median acceptable failure rate was 6.8%. Thus, one-half of the IDCs would have found a failure rate of 6.8% to be acceptable. Seventy-five percent of IDCs would have found a failure rate of 1.6% to be acceptable, and 25% of IDCs would have found a failure rate as high as 11.9% to be acceptable.
  
  
  CONCLUSIONS
  The quantified acceptable failure rates, when used to interpret clinical trial or cohort study results, will help select optimal antimicrobial therapy durations for this specific condition. These findings are a critical step in the development of effective shared decision-making models.
authors.affiliation: Veterans Affairs Maryland Healthcare System, Baltimore, MD 21201, USA. eperence@epi.umaryland.edu
authors.forename: Eli N
authors.initials: EN
authors.lastname: Perencevich
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Harris
authors.forename: Keith S
authors.initials: KS
authors.lastname: Kaye
authors.forename: Douglas D
authors.initials: DD
authors.lastname: Bradham
authors.forename: David N
authors.initials: DN
authors.lastname: Fisman
authors.forename: Laura A
authors.initials: LA
authors.lastname: Liedtke
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Strausbaugh
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology*; D002404:Catheterization; D004866:Equipment Contamination; D006801:Humans; D010818:Practice Patterns, Physicians'; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D011795:Surveys and Questionnaires; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents